These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 26018554)
1. How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes? Schernthaner G; Schernthaner-Reiter MH Diabetes Obes Metab; 2015 Jul; 17(7):613-5. PubMed ID: 26018554 [No Abstract] [Full Text] [Related]
3. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Sharma MD Diabetes Obes Metab; 2015 Jul; 17(7):616-21. PubMed ID: 25690671 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707 [TBL] [Abstract][Full Text] [Related]
5. Clinical decisions. Management of type 2 diabetes--polling results. Schulte JM; Rothaus CS; Adler JN N Engl J Med; 2014 Jan; 370(1):e2. PubMed ID: 24382086 [No Abstract] [Full Text] [Related]
6. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389 [TBL] [Abstract][Full Text] [Related]
7. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis. Ito Y; Ambe K; Hayase T; Kobayashi M; Tohkin M Clin Transl Sci; 2020 May; 13(3):498-508. PubMed ID: 31880866 [TBL] [Abstract][Full Text] [Related]
9. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Lingvay I Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871 [TBL] [Abstract][Full Text] [Related]
10. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor. Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149 [TBL] [Abstract][Full Text] [Related]
11. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968 [TBL] [Abstract][Full Text] [Related]
12. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Guthrie RM Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345 [TBL] [Abstract][Full Text] [Related]
13. Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy. Yamagishi SI Diabetes Metab Res Rev; 2018 Oct; 34(7):e3024. PubMed ID: 29763999 [No Abstract] [Full Text] [Related]
14. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989 [TBL] [Abstract][Full Text] [Related]
16. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. Monami M; Liistro F; Scatena A; Nreu B; Mannucci E Diabetes Obes Metab; 2018 May; 20(5):1213-1222. PubMed ID: 29327406 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Singh AK; Singh R Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238 [TBL] [Abstract][Full Text] [Related]
18. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. Goldenberg RM Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215 [TBL] [Abstract][Full Text] [Related]
19. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Grabner M; Peng X; Geremakis C; Bae J J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969 [TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]